23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
October 30, 2023 08:00 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”) today announced a new, non-exclusive data license with GSK plc (LSE/NYSE: GSK) which...
23andMe to Report FY2024 Second Quarter Financial Results
October 25, 2023 16:05 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
September 27, 2023 16:05 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced two poster...
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
September 14, 2023 07:00 ET
|
23andMe, Inc.
23andMe will offer its Health + Ancestry Service at no cost for up to 1,000 eligible* participants who are 18 years or older and have African ancestry or ancestry from a region where sickle cell...
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
August 31, 2023 17:28 ET
|
23andMe, Inc.
510(k) clearance will allow 23andMe to report an additional 41 genetic variants in the BRCA1 and BRCA2 genes that increase risk for breast, ovarian, prostate and pancreatic cancer Many of these...
23andMe Reports FY2024 First Quarter Financial Results
August 08, 2023 16:05 ET
|
23andMe, Inc.
Reaffirmed Full Year Revenue Guidance and Raised Full Year Guidance for Net Loss and Adjusted EBITDA Deficit Webcast at 4:30 pm ET, August 8, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 08,...
23andMe to Report FY2024 First Quarter Financial Results
July 25, 2023 16:05 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
July 20, 2023 09:23 ET
|
23andMe, Inc.
23andMe is the first and only direct-to-consumer product to offer a suite of FDA-authorized pharmacogenetics reports, with medication insights Lipid-lowering statins are one of the most commonly...
23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks
June 21, 2023 07:00 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report as part...
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
May 25, 2023 16:05 ET
|
23andMe, Inc.
Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE...